Effect of PD-1 Inhibitor Combined with Anlotinib in the Treatment of Ex-tensive Stage Small Cell Lung Cancer
Objective To explore the effect of programmed death receptor 1(PD-1)inhibitors and anlotinib in pa-tients with extensive small cell lung cancer(SCLC).Methods A total of 40 patients with extensive SCLC admitted to Guilin People's Hospital from January 2021 to December 2023 were selected as study objects,and divide into the con-trol group and the observation group by random number table method,with 20 cases in each group.The control group was treated with PD-1 inhibitor(tirizumab)alone,while the observation group was treated with anlotinib based on the control group.Comparing the objective response rates,tumor marker indicators[neuron specific enolase(NSE)and car-cinoembryonic antigen(CEA)],serum indicators[endostatin(ES)and circulating endothelial cells(CEC)],and the inci-dence of adverse reactions between two groups.Results After treatment,the objective remission rate of observation group(75.00%)was higher than that of control group(40.00%),and the difference was statistically significant(χ2=5.012,P<0.05).The levels of NSE,CEA and CEC in the observation group were lower than those in the control group,and the level of ES was higher than that in the control group,and the differences were statistically significance(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Con-clusion For patients with extensive stage SCLC,the regimen of PD-1 inhibitor plus anlotinib is effective,which can ef-fectively inhibit tumor cell growth,increase serum ES level,and reduce CEC level.
Small cell lung cancerExtensive periodProgrammed cell death-ligand 1 inhibitorAnlotinib
NETL
NSTL
万方数据
